CalciMedica, Inc. CALC

NAS: CALC | ISIN: US38942Q2021   17/05/2024
5,450 USD (+0,37%)
(+0,37%)   17/05/2024

13 mei 2024 · CalciMedica Reports First Quarter 2024 Financial Results and Provides Clinical & Corporate Updates · Persbericht

7 mei 2024 · CalciMedica Announces Upcoming Presentation at Digestive Disease Week 2024 · Persbericht

24 april 2024 · CalciMedica Announces Last Patient Enrolled in Phase 2b CARPO Trial of Auxora™ in Acute Pancreatitis · Persbericht

28 maart 2024 · CalciMedica Reports 2023 Financial Results and Provides Clinical & Corporate Updates · Persbericht

13 maart 2024 · CalciMedica Presents Data from Preclinical Studies of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference · Persbericht

29 februari 2024 · CalciMedica Announces Presentation of Data from a Preclinical Study of Auxora in Acute Kidney Injury at the 29th International AKI & CRRT Conference · Persbericht

13 februari 2024 · CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury · Persbericht

7 februari 2024 · CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

22 januari 2024 · CalciMedica Announces Private Placement of up to Approximately $55 Million · Persbericht

9 november 2023 · CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates · Persbericht

2 november 2023 · CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition · Persbericht

6 september 2023 · CalciMedica Announces Upcoming Presentations and Events in September · Persbericht

31 augustus 2023 · CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023 · Persbericht

Mijn selecties